Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%
No Thumbnail Available
Date
2019
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
non-small-cell lung cancer, anti-PD-1, cemiplimab